Palliative radiation therapy for localized prostate symptoms in hormone refractory prostate cancer

Australasian Radiology

Volumn 51, Issue 6, 2007, Pages 584-588

  Hindson, B ^a,b   Turner, S ^a   Do, V ^a  

^a SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

Palliative therapy; Prostate cancer; Radiation therapy

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; MALE; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE FRACTIONATION; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35448967945     PISSN: 00048461     EISSN: 14401673     Source Type: Journal    
DOI: 10.1111/j.1440-1673.2007.01897.x     Document Type: Article

References (19)

1. Fleischmann JD, Catalona WJ. Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate. J Urol 1985 134 : 498 500.
2. Hernes EH, Linja M, Fossa SD, Visakorpi T, Berner A, Winderen M. Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors. BJU Int 2000 86 : 240 47.
3. Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 2004 171 : 668 71.
4. Oefelein MG. Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology 2004 63 : 1117 21.
5. Whitmore WF Jr., Warner JA, Thompson IM Jr. Expectant management of localized prostate cancer. Cancer 1991 67 : 1091 96.
6. Lankford SP, Pollack A, Zagars GK. Radiotherapy for regionally localised hormone refractory prostate cancer. Int J Radiat Oncol Bio Phys 1995 33 : 907 12.
7. Prostate Cancer Treatment. Bethesda: National Cancer Institute, US National Institutes of Health Cited 13 Oct 2006 Available from URL : http://www.cancer.gov
8. Ok J, Meyers FJ, Evans CP. Medical and surgical palliative care of patients with urological malignancies. J Urol 2005 174 : 1177 82.
9. Clarke NW. The management of hormone-relapsed prostate cancer. BJU Int 2003 92 : 860 68.
10. Kamat AM, Huang SF, Bermejo CE et al. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 2003 170 : 1868 71.
11. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantroneplus prednisone for advanced prostate cancer. N Engl J Med 2004 351 : 1502 12.
12. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999 17 : 2506 13.
13. Williams SG, Taylor JMG, Liu N et al. Estimation of the alpha/beta ration of prostate cancer using multivariate analysis of individual fraction size date (Abstract). Australas Radiol 2006 50 : a55 69.
14. Analysis of Censored and Correlated Data (ACCORD). Boffin Software, NSW, Australia, 2007.
15. Fossa SD. Palliative pelvic radiotherapy in patients with hormone-resistant prostatic cancer. Prog Clin Biol Res 1987 243 : 479 85.
16. Furuya F, Akakura K, Akimoto S, Ichikawa T, Ito H. Radiotherapy for local progression in patients with hormone refractory prostate cancer. Int J Urol 1999 6 : 187 91.
17. Gibbons RP, Mason JT, Correa RJ et al. Carcinoma of the prostate: local control with external beam radiation therapy. J Urol 1979 121 : 310 12.
18. Megalli MR, Gursel CD, Demirag H, Veenema RJ, Guttman R. External beam radiotherapy in ureteral obstruction secondary to locally invasive prostate cancer. Urology 1975 3 : 562 4.
19. Michigan S, Catalona WJ. Ureteral obstruction from prostatic carcinoma. Response to endocrine and radiation therapy. J Urol 1977 118 : 773 8.